Skip to Main Content

WASHINGTON — Pharmaceutical companies appear to have succeeded in watering down legislation that would have made it harder for them to protect their medicines by accumulating patents — the latest win for the industry in Congress.

The legislation was aimed at patent “thickets,” in which drug makers obtain a large number of patents to extend their pricing monopoly on any given medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • The proposed legislation would prohibit (or review) patents issued after drug initial approval or patents applied for after initial approval?

Comments are closed.